Axsome Therapeutics has announced that it has successfully completed its late-stage clinical programme evaluating ...

Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor ...

Merck & Co – known as MSD outside the US and Canada – will be gaining exclusive global rights to Hansoh Pharma’s preclinical GLP-1 candidate in a deal worth over $2bn. The agreement gives Merck a ...

Amgen’s Blincyto (blinatumomab) has been granted a licence extension by the Medicines and Healthcare products Regulatory Agency (MHRA) in acute lymphoblastic leukaemia (ALL). The immunotherapy has ...

AI is shooting for the moon and the stars but the real benefits come from anchoring it to the human voice Research conducted at the speed of light, synthetic personas responding instantly to complex ...

AbbVie has announced that it will be expanding its immunology pipeline by acquiring Nimble Therapeutics for $200m. The deal gives AbbVie access to Nimble’s lead asset, an investigational oral peptide ...

Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor tolebrutinib has been granted breakthrough therapy designation by the US Food and Drug Administration (FDA) as a treatment for adults ...

The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis and prurigo nodularis in patients with moderate-to-severe cases of the skin ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to elevate the impact of your medical education efforts in the latest Medical ...

Since the Orphan Drug Act was passed in 1983, pharmaceutical companies have increasingly focused on developing treatments for rare diseases. As a result, competition in the rare disease field is ...

In theory, the principles of omnichannel – personalised content through the right channels to maximise customer experience – are applicable to rare diseases. In practice though, going ‘full throttle’ ...

If you are struggling to navigate the complexity of early commercialisation, rest assured, you are not alone. Clinical trial outcomes remain unpredictable, while evolving regulations and shifting ...